Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) and ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Profitability
This table compares Sunshine Biopharma and ARS Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
Valuation & Earnings
This table compares Sunshine Biopharma and ARS Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sunshine Biopharma | $36.31 million | 0.10 | -$5.97 million | ($10.15) | -0.08 |
| ARS Pharmaceuticals | $84.28 million | 4.87 | -$171.30 million | ($2.18) | -1.89 |
Sunshine Biopharma has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Sunshine Biopharma has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, ARS Pharmaceuticals has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations for Sunshine Biopharma and ARS Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
Sunshine Biopharma currently has a consensus target price of $70.00, indicating a potential upside of 8,617.31%. ARS Pharmaceuticals has a consensus target price of $25.00, indicating a potential upside of 506.06%. Given Sunshine Biopharma’s higher possible upside, equities analysts plainly believe Sunshine Biopharma is more favorable than ARS Pharmaceuticals.
Institutional & Insider Ownership
42.0% of Sunshine Biopharma shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 0.5% of Sunshine Biopharma shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
